University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
Having been retained on the US Trade Representative's (USTR's) Priority Watch List alongside six other countries, the Indian government has undertaken an intellectual property review exercise to assess the risks to innovation and economic growth as posed by the USTR, reports The Pharma Letter’s India correspondent. 1 August 2022
The US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Zoryve (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. 30 July 2022
HIV specialist company ViiV Healthcare today announced week 240 results from the Phase III BRIGHTE study of Rukobia (fostemsavir) in heavily treatment-experienced (HTE) adults with multidrug-resistant HIV-1 infection who have very few treatment options left available to them due to resistance, intolerance, or other safety concerns. 29 July 2022
Danish diabetes care giant Novo Nordisk (NOV: N) today announced headline results from the ONWARDS 3 and ONWARDS 4 Phase IIIa trials with once-weekly insulin icodec in adults with type 2 diabetes. 29 July 2022
US pharma major AbbVie’s shares were up 1.5% at $147.50 pre-market, as it announced financial results for the second quarter ended June 30, 2022. 29 July 2022
Anglo-Swedish drugmaker AstraZeneca was trading nearly 1% lower in London trading early on Friday afternoon after presenting its latest financial results. 29 July 2022
Shares of Canada-based Bausch Health Companies tumbled more than 50% yesterday following an adverse US court ruling in a patent dispute over one of the company’s key drugs. 29 July 2022
US pharma company Acer Therapeutics and its Switzerland-based collaboration partner Relief Therapeutics are confident that their New Drug Application (NDA) for ACER-001 (sodium phenylbutyrate) is back on track. 29 July 2022
US pharma giant Merck & Co recorded second-quarter sales of $14.6 billion, a rise of 28% on the same period in 2021 and well above the FactSet consensus of $13.87 billion. 28 July 2022
Consultancy Vital Transformation has published new research showing that the Build Back Better Act (BBBA) will have a negative impact on patient access to new therapies as funding would be severely curtailed for R&D. 28 July 2022
Japanese pharma giant Takeda today announced strong financial results for the first quarter of fiscal year 2022 (period ended June 30, 2022) and is on track to meet its full-year management guidance. 28 July 2022
Belgium’s largest pharma company UCB this morning posted financial results for the first half of 2022, which it described as “strong,” but investors were not convinced, sending the firm’s shares more than 4% lower to 77.92 euros. 28 July 2022
Shares of Switzerland-based ObsEva fell as much as 80% yesterday, after the women’s health therapy developer revealed it has hit a stumbling block in the US approval of its linzagolix for uterine fibroids. 28 July 2022
Cidara Therapeutics’ shares closed up 11.6% at $0.76 yesterday, when it announced that it has entered into a license agreement with Melinta Therapeutics under which Cidara has granted Melinta an exclusive license to commercialize rezafungin in the USA. 28 July 2022
UK pharma major GSK has presented its first set of financial results since it spun off its consumer health division Haleon earlier this month. 27 July 2022